Citations

Clear

23 citation(s) found for "Santoro, Armando".

CHECKMATE 647: A PHASE 2, OPEN‐LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA
Nayak, Lakshmi , Ferreri, Andrés J.M. , Batlevi, Connie Lee , Batchelor, Tracy T. , Rubenstein, James L. , Johnston, Patrick B. , Ramchandren, Radhakrishnan , Soussain, Carole , Becker, Kevin, Illerhaus, Gerald , Herrera, Alex F. , Masood, Aisha, IWAMOTO, FABIO MASSAITI , Santoro, Armando , Singer, Samuel , Drappatz, Jan , Witzens‐Harig, Mathias , Shipp, Margaret Ann

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 420-421

10.1002/hon.2440_2 Get It

NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW‐UP OF THE PHASE 2 CHECKMATE 205 TRIAL
Fanale, Michelle A. , Engert, Andreas , Younes, Anas , Armand, Philippe , Ansell, Stephen M. , Timmerman, John M. , Ramchandren, Radhakrishnan , Cohen, Jonathon B. , Kato, Kazunobu, Sumbul, Anne, Zinzani, Pier Luigi , Collins, Graham P. , Boer, Jan Paul de , Kuruvilla, John , Savage, Kerry J. , Trněný, Marek , Rodig, Scott J , Shipp, Margaret Ann , Farsaci, Benedetto , Santoro, Armando

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 135-136

10.1002/hon.2437_124 Get It

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
Merryman, Reid W. , Zinzani, Pier Luigi , Carlo‐Stella, Carmelo , Ansell, Stephen M. , Perales, Miguel-Angel, Avigdor, Abraham, Halwani, Ahmad , Houot, Roch, Marchand, Tony , Dhédin, Nathalie , Lescaut, W., Thiebaut‐Bertrand, Anne , François, Sylvie, Stamatoullas‐Bastard, Aspasia, Rohrlich, Pierre-Simon, Wallet, Hélène Labussière, Castagna, Luca , Santoro, Armando , Bachanová, Veronika , Bresler, Scott C., Kim, Harim , Pesek, Emily, Chammas, Marie J, Reynolds, Carol, Ho, Vincent T., Antin, Joseph H., Soiffer, Robert J. , Armand, Philippe , Kim, Haesook T. , Houot, Roch , Rohrlich, Pierre‐Simon , Bresler, Scott C. , Srivastava, Amitabh , Reynolds, Carol, Antin, Joseph H. , Ritz, Jerome , Bachanova, Veronika , Zinzani, Pier Luigi , Santoro, Armando , Castagna, Luca , Carlo-Stella, Carmelo , Merryman, Reid W

Mayo Clinic

Blood | January 10, 2017 | Volume: 129 | Issue: 10 | Pages: 1380-1388

10.1182/blood-2016-09-738385 | PMID 28073785 Get It

Key Points HSCT after PD-1 blockade is feasible, although may be associated with increased early immune toxicity. PD-1 blockade may cause persistent depletion of PD1+ T cells and alterations in T-cell differentiation impacting subsequent treatment.